Citrix AFFECTED by Weak Sales and 4 Stock Analyses Impacting the Market
Tesla Motors, Inc.’s (NASDAQ:TSLA) 5,000 unit expectation in 2012 is viewed by Wunderlich as a stretch, and the firm thinks the company’s Q4 outlook may be aggressive. The firm keeps a Sell rating and a $28 price target on the stock following the company’s Q2 results.
ZaZa Energy (ZAZA) completed its transaction with Hess Corporation (NYSE:HES), which was announced on June 11. The transaction effectively terminates the parties’ 2010 agreements in Texas and, following government approval, those in France, divides the assets of the parties under those agreements; provides a further cash payment to ZaZa today of nearly $69 million, and allows ZaZa to pay down its $100 million senior secured notes, which are due 2017, by $33 million.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) target was increased by Stifel Nicolaus after the company reported higher Q2 Soliris sales than expected and increased its guidance for FY12. The firm views the company’s earnings power as very strong, and it keeps a Buy rating on the stock.
Citrix Systems, Inc. (NASDAQ:CTXS) target was reduced by Stifel Nicolaus after the company reported Q2 results which were stronger than expected, but the company stated that its desktop license revenue growth slowed as a number of areas of its business were weak. The firm still finds the stock’s valuation attractive and keeps its Buy rating.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): According to Baird, Regeneron shares were up a bit yesterday after its Q2 results, and the firm thinks the company offers a convenient time to build/add to positions. The firm mentioned the rising adoption of Eylea which lead to higher earnings estimates and competition from Fovista a long time away. Baird stated the shares should keep working towards $150, and it keeps its Outperform rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.